Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Lieneke F.M. Ariëns's publication output changed over time?
ScholarIQpublication output · 2017–2020
Output grew200% over the shown period — from 1 works in 2017 to 3 in 2020.
1
3
3
3
2017201820192020
What are the most-cited papers on Lieneke F.M. Ariëns?
ScholarIQmost cited works
Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatment
Andreas Wollenberg, Lieneke F.M. Ariëns, Stephan Thurau, Chantal van Luijk, Marlene Seegräber, Marjolein de Bruin‐Weller
The Journal of Allergy and Clinical Immunology In Practice. 2018182 CitationsOPEN ACCESS
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
Daphne S. Bakker, Lieneke F.M. Ariëns, C. van Luijk, Jorien van der Schaft, Judith L. Thijs, Marie L. A. Schuttelaar, Femke van Wijk, Edward F. Knol, Deepak M.W. Balak, Marijke R. van Dijk, Marjolein de Bruin‐Weller
British Journal of Dermatology. 2018154 CitationsOPEN ACCESS
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker, Deepak M.W. Balak, Margreet L. E. Romeijn, T. Kouwenhoven, Marijke Kamsteeg, Barbara Giovannone, Julia Drylewicz, Cynthia C. A. van Amerongen, Evelien M. Delemarre, Edward F. Knol, Femke van Wijk, Stefan Nierkens, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein de Bruin‐Weller
Allergy. 2019150 CitationsOPEN ACCESS
Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology
Lieneke F.M. Ariëns, Florine ML Schussler-Raymakers, Cynthia Frima, Annebeth Flinterman, Eefje A. Hamminga, B.W.M. Arents, Carla A.F.M. Bruijnzeel-Koomen, Marjolein de Bruin‐Weller, Harmieke van Os‐Medendorp
Journal of Medical Internet Research. 2017138 CitationsOPEN ACCESS
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
Lieneke F.M. Ariëns, Jorien van der Schaft, Lotte S. Spekhorst, Daphne S. Bakker, Geertruida L. E. Romeijn, T. Kouwenhoven, Marijke Kamsteeg, Angelique N. Voorberg, Albert J. Oosting, Ilona de Ridder, Annemieke Sloeserwij, Inge Haeck, Judith L. Thijs, Marie L. A. Schuttelaar, Marjolein de Bruin‐Weller
S58727509. 202093 CitationsOPEN ACCESS
Related on ScholarIQ
Utrecht University
Institution
Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatment
Paper
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
Paper
Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
Paper
Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology
Paper
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
Paper